Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18431324 | Polymer Coatings Containing Drug Powder Of Controlled Morphology | February 2024 | October 2025 | Abandon | 20 | 1 | 0 | No | No |
| 18511042 | COMPOSITIONS AND METHODS FOR TREATING ANEMIA | November 2023 | October 2025 | Allow | 23 | 2 | 0 | No | No |
| 18475634 | SURFACE ZWITTERIONIZED SILICONE ANTIFOULING COATING AND PREPARATION METHOD THEREOF | September 2023 | March 2025 | Abandon | 17 | 2 | 1 | No | No |
| 18449358 | GLYCOPROTEINS HAVING LIPID MOBILIZING PROPERTIES AND THERAPEUTIC USES THEREOF | August 2023 | September 2025 | Abandon | 25 | 1 | 1 | No | No |
| 18215698 | SUSTAINED RELEASE FORMULATIONS USING NON-AQUEOUS EMULSIONS | June 2023 | March 2026 | Allow | 32 | 2 | 1 | No | No |
| 18340467 | NIRAPARIB FORMULATIONS | June 2023 | March 2026 | Abandon | 32 | 2 | 1 | No | No |
| 18207289 | COMPOSITE SOLS | June 2023 | May 2025 | Abandon | 23 | 1 | 0 | No | No |
| 18297683 | MEDICAL DEVICE CONTAINING A CAKE COMPOSITION COMPRISING ARIPIPRAZOLE AS AN ACTIVE INGREDIENT, AND A CAKE COMPOSITION COMPRISING ARIPIPRAZOLE AS AN ACTIVE INGREDIENT. | April 2023 | December 2025 | Abandon | 32 | 1 | 1 | No | No |
| 18151402 | COMPOSITION FOR PROMOTING WOUND HEALING | January 2023 | September 2025 | Allow | 32 | 2 | 1 | No | No |
| 18093171 | DRUG RELEASING COATINGS FOR BALLOON CATHETERS | January 2023 | March 2025 | Abandon | 26 | 1 | 0 | No | No |
| 17992634 | PHARMACEUTICAL DELIVERY SYSTEMS FOR HYDROPHOBIC DRUGS AND COMPOSITIONS COMPRISING SAME | November 2022 | April 2025 | Abandon | 28 | 2 | 0 | No | No |
| 17960110 | ADJUVANT FORMULATIONS COMPRISING TLR4 AGONISTS AND METHODS OF USING THE SAME | October 2022 | November 2025 | Abandon | 38 | 2 | 1 | Yes | No |
| 17909638 | APPLICATION OF FULLERENE AND DERIVATIVES THEREOF IN REGULATING INTESTINAL FLORA | September 2022 | December 2025 | Abandon | 39 | 2 | 1 | No | No |
| 17822198 | CANNABIDIOL INFUSED CANDLE | August 2022 | August 2025 | Abandon | 36 | 2 | 1 | No | No |
| 17864827 | AMPHOTERIC COMPOUNDS | July 2022 | September 2025 | Allow | 38 | 1 | 1 | No | No |
| 17840455 | Acid-Labile Chemotherapeutic Compounds and Compositions | June 2022 | March 2025 | Abandon | 33 | 2 | 1 | No | No |
| 17836314 | CONTROLLED RELEASE COMPOSITION AND METHOD | June 2022 | March 2025 | Abandon | 34 | 1 | 1 | No | No |
| 17727301 | PHARMACEUTICAL FORMULATIONS FOR A LIQUID DOSAGE FORM AND A CONTROLLED RELEASE DOSAGE FORM | April 2022 | September 2024 | Abandon | 29 | 1 | 1 | No | No |
| 17718479 | USE OF DIHYDROISOQUINOLINIUM SALTS FOR TREATING KERATIN MATERIALS, COMPOSITIONS AND IMPLEMENTATION PROCESSES | April 2022 | April 2024 | Abandon | 24 | 1 | 1 | No | No |
| 17714010 | COMPOSITIONS AND METHODS FOR TREATMENT OF IMMUNE CHECKPOINT RESISTANT CANCERS | April 2022 | December 2024 | Abandon | 32 | 2 | 1 | No | No |
| 17713134 | Nutritional Compositions For The Management of Hyponatremia | April 2022 | September 2024 | Allow | 30 | 2 | 0 | No | Yes |
| 17677282 | POLYMER PROTEIN MICROPARTICLES | February 2022 | December 2023 | Allow | 21 | 1 | 0 | No | No |
| 17673073 | POLYMER NANOPARTICLE, POLYMER COMPOSITION, METHOD OF MAKING A POLYMER NANOPARTICLE, METHOD FOR TREATMENT OF BACTERIAL BIOFILMS, AND METHOD FOR DETECTION OF BACTERIAL BIOFILMS | February 2022 | November 2024 | Allow | 33 | 3 | 0 | No | No |
| 17592162 | PROTECTION OF MATERIALS BY SPHINGOSINE BASED COMPOUNDS | February 2022 | December 2023 | Allow | 22 | 1 | 0 | No | No |
| 17589943 | PHOTO-ACTIVATABLE COMPOUND, ITS PREPARATION AND THERAPEUTIC USE | February 2022 | May 2025 | Allow | 40 | 3 | 1 | Yes | No |
| 17558867 | TRIGGERABLE HYDROGEL COMPOSITIONS AND RELATED METHODS | December 2021 | October 2023 | Abandon | 22 | 1 | 0 | No | No |
| 17544492 | BIOADHESIVE HYDROGELS | December 2021 | July 2024 | Allow | 31 | 3 | 0 | No | No |
| 17506997 | COMPOSITION COMPRISING IRON OXIDE MAGNETIC PARTICLES FOR A TREATMENT OF LIVER CANCER | October 2021 | May 2025 | Abandon | 42 | 3 | 1 | No | No |
| 17450683 | ARIPIPRAZOLE PRODRUG COMPOSITION | October 2021 | February 2026 | Allow | 52 | 4 | 1 | No | No |
| 17466204 | Pharmaceutical Compositions of Fumaric Acid Esters | September 2021 | August 2024 | Abandon | 36 | 2 | 1 | No | No |
| 17411284 | ASTAXANTHIN NANOEMULSION AND MANUFACTURING METHOD THEREOF | August 2021 | October 2024 | Allow | 38 | 3 | 1 | No | No |
| 17408612 | C3-C5 N-ALKYL-GAMMA-BUTYROLACTAM CONTAINING ANTIMICROBIAL COMPOSITIONS AND METHODS OF USING SAME | August 2021 | March 2024 | Allow | 31 | 1 | 1 | Yes | No |
| 17408598 | ANTIMICROBIAL COMPOSITIONS CONTAINING SOLVENTS INCLUDING A C3-C5 N-ALKYL-GAMMA-BUTYROLACTAM | August 2021 | March 2024 | Allow | 31 | 1 | 1 | Yes | No |
| 17408945 | Low-Dose Doxepin Formulations And Methods Of Making And Using The Same | August 2021 | July 2024 | Abandon | 35 | 5 | 1 | No | No |
| 17392088 | SHEAR-THINNING COMPOSITIONS AS AN INTRAVASCULAR EMBOLIC AGENT | August 2021 | May 2022 | Allow | 10 | 2 | 0 | No | No |
| 17373354 | TRIPLET-TRIPLET ANNIHILATION UPCONVERSION SYSTEM, AND COMPOSITIONS AND METHODS THEREOF FOR DRUG DELIVERY | July 2021 | September 2023 | Allow | 27 | 2 | 0 | No | No |
| 17367962 | DRUG FOR USE AGAINST THE NOVEL CORONAVIRUS DISEASE, COVID-19 | July 2021 | May 2023 | Abandon | 22 | 1 | 0 | No | No |
| 17358554 | NEW HYDROGELS HAVING A SILYLATED STRUCTURE, AND METHOD FOR OBTAINING SAME | June 2021 | August 2025 | Abandon | 50 | 4 | 1 | No | No |
| 17354742 | GLYCOPROTEINS HAVING LIPID MOBILIZING PROPERTIES AND THERAPEUTIC USES THEREOF | June 2021 | September 2023 | Abandon | 27 | 1 | 1 | No | No |
| 17345277 | METHOD OF KILLING MICROBES USING C3-C5 N-ALKYL-GAMMA-BUTYROLACTAMS AND ANTIMICROBIAL COMPOSITIONS CONTAINING SAME | June 2021 | October 2025 | Allow | 52 | 2 | 1 | No | No |
| 17344325 | ORTHOPEDIC IMPLANT HAVING A CRYSTALLINE CALCIUM PHOSPHATE COATING AND METHODS FOR MAKING THE SAME | June 2021 | June 2023 | Allow | 24 | 1 | 0 | No | No |
| 17342085 | Long chain glycolipids useful to avoid perishing or microbial contamination of materials | June 2021 | February 2022 | Allow | 9 | 1 | 0 | No | No |
| 17321168 | CYTOSOLIC DELIVERY OF PEPTIDES USING PROTEIN TRANSDUCTION DOMAIN MIMICS | May 2021 | May 2024 | Allow | 36 | 1 | 1 | No | No |
| 17316244 | LOW PARTICULATE LUBRICIOUS COATING WITH VINYL PYRROLIDONE AND ACIDIC POLYMER-CONTAINING LAYERS | May 2021 | May 2025 | Allow | 48 | 4 | 1 | No | No |
| 17307671 | METHODS OF PREPARING HIGHLY CHARGED POLYETHYLENIMINE AND COMPOSITIONS AND USES THEREOF | May 2021 | November 2022 | Allow | 18 | 4 | 1 | No | No |
| 17243769 | Coatings Containing Multiple Drugs | April 2021 | August 2023 | Allow | 27 | 2 | 0 | No | No |
| 17282439 | NEW MEDICAL USE OF OXALATE-REDUCING BACTERIA | April 2021 | November 2023 | Abandon | 32 | 1 | 0 | No | No |
| 17281437 | FORMULATION COMPRISING OZONISED OIL IN THE TREATMENT OF A TUMOUR | March 2021 | April 2025 | Abandon | 49 | 2 | 1 | Yes | No |
| 17278930 | LIQUID POLYMER DELIVERY SYSTEM FOR EXTENDED ADMINISTRATION OF DRUGS | March 2021 | June 2025 | Abandon | 51 | 3 | 1 | No | No |
| 17206273 | SALVIANOLIC ACID-GELATIN CONJUGATE HYDROGEL PARTICLES | March 2021 | April 2024 | Allow | 37 | 2 | 1 | No | No |
| 17204914 | COMPOSITION FOR PROMOTING WOUND HEALING AND PREPARING METHOD THEREOF | March 2021 | December 2022 | Allow | 21 | 1 | 1 | Yes | No |
| 17186664 | Phytic Acid Ester Derivative | February 2021 | September 2023 | Abandon | 31 | 2 | 1 | Yes | No |
| 17182504 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, CONTAINING NITROGEN MONOXIDE-SENSITIVE ACRYLAMIDE-BASED POLYMER | February 2021 | July 2022 | Allow | 16 | 1 | 0 | No | No |
| 17177202 | Antimicrobial nanostructured silver perovskite oxides | February 2021 | April 2025 | Abandon | 50 | 5 | 1 | No | No |
| 17176527 | High Shine, Long Wear Color Cosmetic Compositions | February 2021 | November 2024 | Abandon | 45 | 1 | 1 | No | No |
| 17267215 | SUCROFERRIC OXYHYDROXIDE-CONTAINING GRANULES AND PHARMACEUTICAL COMPOSITION | February 2021 | September 2024 | Allow | 43 | 3 | 0 | No | No |
| 17157115 | Polymer Coatings Containing Drug Powder Of Controlled Morphology | January 2021 | October 2023 | Allow | 33 | 2 | 0 | No | No |
| 17141719 | DRUG RELEASING COATINGS FOR BALLOON CATHETERS | January 2021 | January 2023 | Allow | 25 | 2 | 0 | No | No |
| 17140718 | DRUG RELEASING COATINGS FOR BALLOON CATHETERS | January 2021 | January 2023 | Allow | 25 | 3 | 0 | No | Yes |
| 17252487 | COSMETIC COMPOSITION COMPRISING ANIONIC, NON-IONIC AND AMPHOTERIC SURFACTANTS, AT LEAST TWO ORGANOSILANES AND ASSOCIATIVE CATIONIC POLYMERS, COSMETIC TREATMENT PROCESS AND USE | December 2020 | April 2024 | Abandon | 40 | 1 | 1 | No | No |
| 17120965 | POLYGALA EXTRACT FOR THE TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER | December 2020 | October 2023 | Allow | 34 | 2 | 0 | No | No |
| 17116983 | STABLE PHARMACEUTICAL COMPOSITIONS COMPRISING A PYRIMIDINE-SULFAMIDE | December 2020 | November 2022 | Allow | 24 | 1 | 0 | No | No |
| 17114767 | HAIR STRENGTHENING COMPOSITION | December 2020 | September 2023 | Allow | 33 | 2 | 1 | No | No |
| 17104566 | Sustained Release Formulations Using Non-Aqueous Emulsions | November 2020 | March 2023 | Allow | 28 | 2 | 1 | No | No |
| 17055768 | CONJUGATES COMPRISING A TEMPERATURE-RESPONSIVE POLYMER AND A LIGAND CAPABLE OF BINDING ERGOSTEROL | November 2020 | July 2024 | Allow | 44 | 4 | 1 | Yes | No |
| 17086862 | DRUG DELIVERY SYSTEMS COMPRISING SOLID SOLUTIONS OF WEAKLY BASIC DRUGS | November 2020 | July 2024 | Allow | 45 | 3 | 1 | No | No |
| 17072707 | BULK POLYETHYLENE GLYCOL COMPOSITIONS | October 2020 | June 2023 | Allow | 32 | 2 | 1 | No | No |
| 17047542 | COMPOSITIONS AND METHODS FOR INTRANASAL DELIVERY OF PREGNENOLONE | October 2020 | July 2023 | Abandon | 33 | 2 | 1 | No | No |
| 17045317 | PROTEIN FUNCTIONALIZED HYALURONIC ACID COATED CHITOSAN NANOPARTICLE AND METHOD OF PREPARATION | October 2020 | November 2023 | Abandon | 37 | 2 | 1 | No | No |
| 17063327 | Nutritional Compositions For The Management of Hyponatremia | October 2020 | February 2022 | Allow | 16 | 1 | 0 | No | No |
| 17045469 | REFILLABLE DRUG DELIVERY BY AFFINITY HOMING | October 2020 | July 2023 | Allow | 33 | 2 | 1 | No | No |
| 17043000 | PROCESS FOR CURL-RELAXING AND/OR STRAIGHTENING KERATIN FIBRES, USING A THIOL-BASED REDUCING AGENT AND A DICARBOXYLIC ACID DERIVATIVE, AND STRAIGHTENING KIT | September 2020 | July 2024 | Abandon | 45 | 2 | 1 | Yes | No |
| 17029147 | Cosmetic Adhesive Compositions | September 2020 | July 2022 | Allow | 22 | 1 | 0 | No | No |
| 17006262 | Method for the preparation of a 1,7-bis (4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione system in polysorbates for the formation of micelles in an aqueous medium aimed at the properties of the bioavailability of curcuminoids | August 2020 | September 2024 | Allow | 49 | 5 | 1 | No | No |
| 16976270 | Pharmaceutical Composition with Excellent Storage Stability | August 2020 | May 2025 | Allow | 57 | 2 | 0 | No | No |
| 16971863 | Adhesive Composition | August 2020 | March 2024 | Abandon | 43 | 0 | 1 | No | No |
| 16996183 | DRUG RELEASING COATINGS FOR MEDICAL DEVICES | August 2020 | February 2022 | Allow | 18 | 1 | 0 | No | No |
| 16966793 | ANTIBACTERIAL AND SPERMICIDAL LUBRICANT | July 2020 | September 2023 | Abandon | 38 | 2 | 1 | No | No |
| 16966453 | OCULAR INSERTS COMPRISING A COVALENTLY LINKED STEROID DIMER | July 2020 | November 2022 | Allow | 28 | 1 | 1 | Yes | No |
| 16919728 | GLYCOPROTEINS HAVING LIPID MOBILIZING PROPERTIES AND THERAPEUTIC USES THEREOF | July 2020 | September 2021 | Abandon | 15 | 1 | 1 | No | No |
| 16911655 | POLYMERIC DRUG CONJUGATES WITH TETHER GROUPS FOR CONTROLLED DRUG DELIVERY | June 2020 | April 2022 | Abandon | 21 | 1 | 0 | No | No |
| 16908940 | POROUS PARTICLE AND METHOD FOR PRODUCING THE SAME, AND PHARMACEUTICAL COMPOSITION | June 2020 | January 2023 | Allow | 30 | 3 | 1 | No | No |
| 16904246 | ARIPIPRAZOLE PRODRUG COMPOSITION | June 2020 | September 2021 | Allow | 14 | 2 | 0 | No | No |
| 16899255 | CLOSED CELL FOAMS INCLUDING POLY-4-HYDROXYBUTYRATE AND COPOLYMERS THEREOF | June 2020 | November 2021 | Allow | 17 | 2 | 0 | No | No |
| 16769501 | METHODS OF CANCER TREATMENT VIA REGULATED FERROPTOSIS | June 2020 | April 2024 | Abandon | 46 | 2 | 1 | No | No |
| 16882239 | PARTICLES | May 2020 | March 2026 | Abandon | 60 | 9 | 1 | Yes | No |
| 16765883 | Oral Pharmaceutical Composition of an NK-1 Antagonist | May 2020 | April 2023 | Abandon | 34 | 2 | 1 | No | No |
| 16856893 | METHODS AND COMPOSITIONS INHIBITING ENVELOPED VIRUSES USING HIGH MOLECULAR WEIGHT HYDROPHOBICALLY MODIFIED ALKALI SWELLABLE EMULSION POLYMERS | April 2020 | January 2024 | Allow | 44 | 3 | 1 | No | No |
| 16755866 | NANOVECTORS AND USES | April 2020 | August 2023 | Allow | 40 | 2 | 1 | No | No |
| 16842855 | METHOD FOR IMPROVING PHARMACOKINETICS | April 2020 | December 2020 | Allow | 8 | 1 | 0 | Yes | No |
| 16835940 | PROCESS FOR PRODUCING MICROEMULSION SYSTEM OF NANO ESSENTIAL OIL | March 2020 | January 2023 | Allow | 34 | 2 | 1 | No | No |
| 16650948 | NIRAPARIB FORMULATIONS | March 2020 | February 2023 | Allow | 35 | 3 | 1 | No | No |
| 16816027 | MEAT TREATMENT | March 2020 | November 2023 | Abandon | 44 | 2 | 1 | No | No |
| 16815458 | Method and System for Treating Vulvodynia | March 2020 | August 2025 | Allow | 60 | 4 | 1 | No | No |
| 16814489 | PHOSPHINOGOLD(I) COMPLEXES AND METHODS OF TREATING CANCER | March 2020 | June 2021 | Allow | 16 | 0 | 1 | No | No |
| 16641559 | TRIPLET-TRIPLET ANNIHILATION UPCONVERSION SYSTEM, AND COMPOSITIONS AND METHODS THEREOF FOR DRUG DELIVERY | February 2020 | April 2021 | Allow | 13 | 1 | 1 | No | No |
| 16779901 | Low-Dose Doxepin Formulations And Methods Of Making And Using The Same | February 2020 | December 2020 | Allow | 11 | 1 | 0 | No | No |
| 16778101 | LONG CHAIN GLYCOLIPIDS USEFUL TO AVOID PERISHING OR MICROBIAL CONTAMINATION OF MATERIALS | January 2020 | July 2022 | Allow | 30 | 3 | 1 | Yes | No |
| 16634486 | NANOSCALE METAL-ORGANIC LAYERS AND METAL-ORGANIC NANOPLATES FOR X-RAY INDUCED PHOTODYNAMIC THERAPY, RADIOTHERAPY, RADIODYNAMIC THERAPY, CHEMOTHERAPY, IMMUNOTHERAPY, AND ANY COMBINATION THEREOF | January 2020 | July 2023 | Allow | 41 | 2 | 1 | No | No |
| 16632759 | NANOPARTICLE COMPOSITIONS | January 2020 | January 2023 | Allow | 36 | 4 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner WHEELER, THURMAN MICHAEL.
With a 30.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 18.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner WHEELER, THURMAN MICHAEL works in Art Unit 1619 and has examined 638 patent applications in our dataset. With an allowance rate of 43.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 42 months.
Examiner WHEELER, THURMAN MICHAEL's allowance rate of 43.3% places them in the 8% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by WHEELER, THURMAN MICHAEL receive 2.92 office actions before reaching final disposition. This places the examiner in the 85% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by WHEELER, THURMAN MICHAEL is 42 months. This places the examiner in the 17% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +26.1% benefit to allowance rate for applications examined by WHEELER, THURMAN MICHAEL. This interview benefit is in the 73% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 14.3% of applications are subsequently allowed. This success rate is in the 10% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 33.3% of cases where such amendments are filed. This entry rate is in the 49% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 94.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 69% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 62.3% of appeals filed. This is in the 40% percentile among all examiners. Of these withdrawals, 54.5% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 66.9% are granted (fully or in part). This grant rate is in the 75% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.3% of allowed cases (in the 56% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.7% of allowed cases (in the 58% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.